Raynaud's phenomenon is a clinically important manifestation in patients with systemic sclerosis. This protocol addresses the first-line therapeutic approach for this specific presentation (SSc-RP).
The patient has systemic sclerosis with concurrent Raynaud's phenomenon — a distinct complication requiring targeted vasomotor management guided by evidence-based recommendations.
Guideline evidence supports a specific class of calcium antagonist as first-line therapy for SSc-RP. The complete protocol — including the recommended agent, formulation, and clinical context — is available below.
DOI: 10.1136/ard-2024-226430
Dihydropyridine-type calcium antagonists, usually oral nifedipine, should be used as first-line therapy for SSc-RP.
View source ↗